ArticleFungal biology and biotechnology2024
Patent landscape analysis for materials based on fungal mycelium: a guidance report on how to interpret the current patent situation.
Article in Fungal biology and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Fungal Innovations-Advancing Sustainable Materials, Genetics, and Applications for Industry.Journal of fungi (Basel, Switzerland) · 2025Review
- Indigenizing fungal biotechnology for planetary health: an opinion paper.Fungal biology and biotechnology · 2025Article
- Uncovering the transcriptional landscape of Fomes fomentarius during fungal-based material production through gene co-expression network analysis.Fungal biology and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent advancements in the collaboration between two scientific disciplines-fungal biotechnology and materials sciences-underscore the potential of fungal mycelium as renewable resource for sustainable biomaterials that can be harnessed in different industries. As fungal mycelium can be biotechnologically obtained from different filamentous fungi and is as a material very versatile, respective research and commercial application should be thriving. However, some granted patents in the field of fungal mycelium-based materials have caused uncertainty in the community as to which subject matter is patent-protected and for how long the protection is expected to last.
resultsThis opinion paper therefore maps the patent landscape of fungal mycelium-based materials with a specific focus on technical applications including building construction, insulation, packaging, and the like. We provide an overview of granted patents (73) and pending applications (34) related to granted patents, the dominant patent portfolios (five, with the number of patents and/or applications per owner between six and 44), the patent owners, and highlight the key claims formulated to protect the inventions. Additionally, we outline various options towards an increased activity in the field.
conclusionPatent developments in the field leave the impression that fungal materials, despite their high potential as renewable and biodegradable materials, have been held back due to patent over-protection. Considering the need for replacing current petroleum-based materials with renewable biomaterials, coordinated efforts may be called for to intensify efforts in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.